Monthly Archives: January 2017

http://www.lslog.com/pfizers-prevnar-misses-big-on-q4-sales-dragging-vaccines-unit-down-with-it/Pfizer's Prevnar misses big on Q4 sales, dragging vaccines unit down with it

Pfizer's Prevnar misses big on Q4 sales, dragging vaccines unit down with it

Pfizer’s Prevnar misses big on Q4 sales, dragging vaccines unit down with it Pfizer’s Prevnar misses big on Q4 sales, dragging vaccines unit down with it esagonowsky Tue, 01/31/2017 – […]

http://www.lslog.com/sanofi-novo-and-lilly-face-class-action-over-astounding-insulin-price-hikes/Sanofi, Novo and Lilly face class action over 'astounding' insulin price hikes

Sanofi, Novo and Lilly face class action over 'astounding' insulin price hikes

Sanofi, Novo and Lilly face class action over ‘astounding’ insulin price hikes Sanofi, Novo and Lilly face class action over ‘astounding’ insulin price hikes esagonowsky Tue, 01/31/2017 – 10:13 […]

http://www.lslog.com/lawmakers-pressure-trump-on-fda-hiring-freeze/Lawmakers pressure Trump on FDA hiring freeze

Lawmakers pressure Trump on FDA hiring freeze

Lawmakers pressure Trump on FDA hiring freeze Lawmakers pressure Trump on FDA hiring freeze badams Tue, 01/31/2017 – 10:03 Source: FierceMedicalDevices News Lawmakers pressure Trump on FDA hiring freeze

http://www.lslog.com/sanofis-meningococcal-vax-rivalry-with-novartis-ends-in-61-5m-class-action-settlement/Sanofi's meningococcal vax rivalry with Novartis ends in $61.5M class-action settlement

Sanofi's meningococcal vax rivalry with Novartis ends in $61.5M class-action settlement

Sanofi’s meningococcal vax rivalry with Novartis ends in .5M class-action settlement Sanofi’s meningococcal vax rivalry with Novartis ends in $61.5M class-action settlement esagonowsky Mon, 01/30/2017 – 16:00 Source: Fierce […]

http://www.lslog.com/inherited-pay-for-delay-penalties-are-getting-expensive-for-cash-strapped-teva/Inherited pay-for-delay penalties are getting expensive for 'cash-strapped' Teva

Inherited pay-for-delay penalties are getting expensive for 'cash-strapped' Teva

Inherited pay-for-delay penalties are getting expensive for ‘cash-strapped’ Teva Inherited pay-for-delay penalties are getting expensive for ‘cash-strapped’ Teva chelfand Mon, 01/30/2017 – 11:14 Source: Fierce Pharma Inherited pay-for-delay penalties […]

http://www.lslog.com/phase-3-hit-tees-fibrogen-astrazeneca-up-for-anemia-filing/Phase 3 hit tees FibroGen, AstraZeneca up for anemia filing

Phase 3 hit tees FibroGen, AstraZeneca up for anemia filing

Phase 3 hit tees FibroGen, AstraZeneca up for anemia filing Phase 3 hit tees FibroGen, AstraZeneca up for anemia filing nick.paul.taylor Mon, 01/30/2017 – 09:09 Source: FierceMedicalDevices News Phase […]

http://www.lslog.com/scancell-taps-lung-cancer-nonprofit-to-accelerate-trial-recruitment/Scancell taps lung cancer nonprofit to accelerate trial recruitment

Scancell taps lung cancer nonprofit to accelerate trial recruitment

Scancell taps lung cancer nonprofit to accelerate trial recruitment Scancell taps lung cancer nonprofit to accelerate trial recruitment phil Mon, 01/30/2017 – 08:52 Source: FierceMedicalDevices News Scancell taps lung […]

http://www.lslog.com/novo-nordisk-to-set-up-115m-rd-center-at-oxford-uni/Novo Nordisk to set up £115M R&D center at Oxford Uni

Novo Nordisk to set up £115M R&D center at Oxford Uni

Novo Nordisk to set up £115M R&D center at Oxford Uni Novo Nordisk to set up £115M R&D center at Oxford Uni nick.paul.taylor Mon, 01/30/2017 – 03:21 Source: FierceMedicalDevices […]

http://www.lslog.com/roche-newcomer-tecentriq-has-bristols-opdivo-bleeding-lung-cancer-share-execs/Roche newcomer Tecentriq has Bristol's Opdivo bleeding lung cancer share: execs

Roche newcomer Tecentriq has Bristol's Opdivo bleeding lung cancer share: execs

Roche newcomer Tecentriq has Bristol’s Opdivo bleeding lung cancer share: execs Roche newcomer Tecentriq has Bristol’s Opdivo bleeding lung cancer share: execs chelfand Fri, 01/27/2017 – 11:36 Source: Fierce […]

http://www.lslog.com/abbvies-q4-sales-miss-the-mark-as-cancer-hep-c-meds-lag/AbbVie's Q4 sales miss the mark as cancer, hep C meds lag

AbbVie's Q4 sales miss the mark as cancer, hep C meds lag

AbbVie’s Q4 sales miss the mark as cancer, hep C meds lag AbbVie’s Q4 sales miss the mark as cancer, hep C meds lag chelfand Fri, 01/27/2017 – 10:53 […]